CareDx (NASDAQ:CDNA) CEO John Walter Hanna, Jr. Sells 10,156 Shares

CareDx, Inc. (NASDAQ:CDNA) CEO John Walter Hanna, Jr. sold 10,156 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $21.05, for a total value of $213,783.80. Following the completion of the transaction, the chief executive officer owned 616,885 shares in the company, valued at approximately $12,985,429.25. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

CareDx Stock Performance

Shares of CDNA opened at $20.20 on Wednesday. The stock has a 50 day moving average price of $18.64 and a 200 day moving average price of $15.84. CareDx, Inc. has a one year low of $10.96 and a one year high of $25.55. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of 16.97 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.15. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The company had revenue of $100.06 million for the quarter, compared to analyst estimates of $95.25 million. During the same quarter last year, the firm posted ($0.14) EPS. The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. On average, analysts predict that CareDx, Inc. will post -0.9 earnings per share for the current year.

Institutional Investors Weigh In On CareDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aberdeen Group plc purchased a new position in shares of CareDx during the 4th quarter worth $6,506,000. Allspring Global Investments Holdings LLC boosted its stake in CareDx by 9.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock worth $365,000 after buying an additional 1,675 shares during the period. SG Americas Securities LLC increased its position in shares of CareDx by 99.9% during the fourth quarter. SG Americas Securities LLC now owns 27,657 shares of the company’s stock valued at $521,000 after acquiring an additional 13,823 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of CareDx in the 3rd quarter valued at approximately $31,000. Finally, Virtus Advisers LLC raised its stake in shares of CareDx by 843.6% in the 3rd quarter. Virtus Advisers LLC now owns 40,564 shares of the company’s stock valued at $590,000 after acquiring an additional 36,265 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have commented on CDNA shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of CareDx in a report on Monday, December 29th. BTIG Research upped their price target on CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 18th. Wall Street Zen raised CareDx from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Finally, Craig Hallum cut CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price for the company. in a report on Tuesday, January 6th. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, CareDx has an average rating of “Hold” and an average target price of $26.67.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.